Chronic Kidney Disease (Stages 3b-5)NCT07760285
Virtual Reality Versus Intradialytic Neuromuscular Electrical Stimulation on Renin Hormone in Chronic Kidney Patients
A study testing Virtual Reality session, intradialytic neuromuscular electrical stimulation and Maitland Mobilization in people with Chronic Kidney Disease (Stages 3b-5) and Hemodialysis, run by Adly A Adam at 1 site in Egypt.
Trial summary
Worldwide accelerated advances in physical rehabilitation of chronic kidney disease; particularly whom undergoing hemodialysis. Multimodal therapeutic approaches may maximize their recovery through preliminary evidence indicating both intradialytic neuromuscular electrical stimulation or Virtual reality-based… Read more about this study
- Who is it for?
- Ages 40 to 65 years
- Conditions the study is for
- Chronic Kidney Disease (Stages 3b-5), Hemodialysis, Shoulder Adhesive Capsulitis
- What is being tested?
- Virtual Reality session, intradialytic neuromuscular electrical stimulation and Maitland Mobilization
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2026to 1 Aug 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient underwent modified radical mastectomy from one month earlier.
- Patients suffering from shoulder pain and limited range of motion were included in current study.
- Patients' age ranged from 40 to 65 years.
- Patients of both genders.
- All patients were free of any comorbidities such as systemic or neurological diseases.
Who cannot join
- Patient underwent chemotherapy.
- Diabetic patients.
- Patient have any comorbidities such as systemic or neurological diseases.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Virtual Reality Versus Intradialytic Neuromuscular Electrical Stimulation On Renin Hormone in Chronic Kidney Disease
Worldwide accelerated advances in physical rehabilitation of chronic kidney disease; particularly whom undergoing hemodialysis. Multimodal therapeutic approaches may maximize their recovery through preliminary evidence indicating both intradialytic neuromuscular electrical stimulation or Virtual reality-based rehabilitation (VRBR) is a relatively new method that might make it easier to simulate doing functional tasks than conventional rehabilitation.
Read the detailed description
In line to determine efficacy of virtual reality versus intradialytic neuromuscular electrical stimulation on renin hormone levels in patients with chronic kidney disease, a 60-patients of both genders with chronic kidney disease whom undergoing hemodialysis three times per week their age (50-60y) were randomly allocated into two groups. Group A received Virtual reality, plus conventional physical therapy protocol, Group B received intradialytic neuromuscular electrical stimulation protocol; 3 session per week. Group C received Conventional Physical Therapy protocol. Treatment protocol extended for eight weeks, where evaluation involving renin hormone test, upper extremity musculature strength using dynamometer, kidney glomerular filtration rate.
- Being tested
- Virtual Reality session, intradialytic neuromuscular electrical stimulation, Maitland Mobilization, Conventional Physical Therapy protocol
- Keywords
- Digital goniometer, shoulder dysfunction, shoulder pain and disability index, Virtual reality, Chronic kidney disease, Dynamometer, Renin Hormone, Intradialytic neuromuscular electrical stimulation, Maitland Mobilization
- Medical subject headings
- Renal Insufficiency, Chronic, Bursitis, Shoulder Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual Reality sessionOther
virtual reality exercise programs that was applied in form of a series of kinect adventure games and designed for Xbox 360 kinect console, and projected onto a 24-inch screen LED-Lit monitor; along 30-40 min, 3 sets/ week along 8 weeks
intradialytic neuromuscular electrical stimulationOther
The portable Chattanooga electric stimulation device has been switched on and adjusted the current amplitude/ strength from 5-140 mA according to each patients' targeted strength, frequency seated at 5Hz over shoulder musculatures under direct supervision along 30 minutes for each session, 3 sessions per week over 8 weeks
Maitland MobilizationOther
maitland graded oscillation technique that was applied to the glenohumeral (GH) joint in form of anteroposterior (A-P), posteroanterior (P-A), and longitudinal caudal glides; as well regarding sternoclavicular joint 'Posterior and anterior glide', plus acromioclavicular joint; anterior glide, only fifteen glides, along 30-40 min, 3 sets/ week along 8 weeks
Conventional Physical Therapy protocolOther
Active range of motion exercises; along 30-40 min, 3 sets/ week along 8 weeks
| Study group | Role | What they receive |
|---|---|---|
| Experimental Group A (Virtual reality) | Experimental | 20 participants suffering from CKD received Virtual reality by Xbox Kinect 360 console, plus conventional physical therapy protocol, along 8 weeks Receives: Other: Virtual Reality session; Other: Conventional Physical Therapy protocol |
| Experimental Group B (intradialytic neuromuscular electrical stimulation ) | Experimental | 20 participants suffering from CKD received intradialytic neuromuscular electrical stimulation protocol, for 30 minutes, 3 times per week over 8 weeks. Receives: Other: intradialytic neuromuscular electrical stimulation; Other: Conventional Physical Therapy protocol |
| Experimental Group A (conventional physical therapy protocol including Maitland mobilization) | Experimental | 20 participants suffering from CKD received Maitland mobilization, plus Conventional physical therapy protocol, along 30-40 minutes, 3 sets/ week over 8 weeks. Receives: Other: Maitland Mobilization; Other: Conventional Physical Therapy protocol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Renin Hormone test
SIEMENS, Blood Analyzer, Model: DCA Vantage, MPN: 4.6.0.0, USA; Hemostasis system equipment is manufactured by Siemens manumitted company, Germany for both renin hormone test and glomerular filtration rate monitoring among CKD patients collected samples early morning by responsible nursing staff from renal vein through the already inserted catheter/ or directly from patients' veins
Measured: At pretreatment At post treatment after 8 weeks of the study protocol
Secondary outcomes (3)
Shoulder Range of Motion
Digital goniometer tool6 inches, 2.53 oz, 1x360 degree stainless steel device is a 180 °or 360 ° protractor with one axis that joins two arms. One arm is stationary and the other arm is movable around the axis or fulcrum of the protractor. It used for measurement of shoulder ROM (flexion, abduction and external rotation)
Measured: At pretreatment At posttreatment after 8 weeks of the study protocol
Shoulder muscular strength
digital dynamometers (5710e/5715, Takei Scientific Instruments Co. Ltd., Niigata, Japan) measuring range is 0-300 kilogram per force, minimum measurement unit 1 kilogram per force, display on scale plate, with dimensions approximately 315 millimeters width, 315 millimeters depth, and 328 millimeters height, and the total weight approximately 3.7 kilograms including weight of handle for shoulder flexors, abductors, and external rotator strength assessment
Measured: At pretreatment At posttreatment after 8 weeks of study protocol
The shoulder pain intensity and functional disability assessment
The shoulder pain intensity and functional disability assessment using the Shoulder pain and disability index questionnaire with 13 items assessing pain level and extent of difficulty with ADLs requiring the use of the upper extremities. The pain subscale has 5-items and the Disability subscale has 8-items. The total SPADI score was expressed as a percentage. A score of 0 indicates best 100 indicates worst. A higher score showed more disability. In scoring , any question missed was taken out of the total score of each subscale; if one question was omitted in the pain section, the total score was divided by 40
Measured: At pretreatment At posttreatment of 8 weeks of the study protocol
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2026
- Study start1 Jan 2026
- Primary completion1 Jul 2026
- Study completion1 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney Disease (Stages 3b-5)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, randomized, controlled trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Adly A Adam
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Adly A Adam, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07760285
- Sponsor's protocol ID
- HSH000707
- Status last verified
- Oct 2026
- First submitted
- 7 Aug 2026
- Last updated
- 14 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No